Picture of Evoke Pharma logo

EVOK Evoke Pharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-13.83%
3m-52.25%
6m-50.61%
1yr-82.57%
Volume Change (%)
10d/3m+43.84%
Price vs... (%)
52w High-75.12%
50d MA-11.23%
200d MA-48.06%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-184.25%
Return on Equity-1035.45%
Operating Margin-143.44%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Evoke Pharma EPS forecast chart

Profile Summary

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
January 29th, 2007
Public Since
September 25th, 2013
No. of Shareholders
5
No. of Employees
4
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
8,477,801

EVOK Share Price Performance

Upcoming Events for EVOK

Evoke Pharma Inc Annual Shareholders Meeting

Q1 2024 Evoke Pharma Inc Earnings Release

Q2 2024 Evoke Pharma Inc Earnings Release

Similar to EVOK

Picture of 60 Degrees Pharmaceuticals logo

60 Degrees Pharmaceuticals

us flag iconNASDAQ Capital Market

Picture of Aadi Bioscience logo

Aadi Bioscience

us flag iconNASDAQ Capital Market

Picture of Acasti Pharma logo

Acasti Pharma

us flag iconNASDAQ Capital Market

Picture of Agriforce Growing Systems logo

Agriforce Growing Systems

us flag iconNASDAQ Capital Market

Picture of Akanda logo

Akanda

us flag iconNASDAQ Capital Market

FAQ